Log in
Request a free trial
Request a free trial
Log in
Products
Solutions
Data
News & Analysis
About
News & Analysis
driven by the PitchBook Platform
subscribe
Private Equity
Venture Capital
M&A
More
reports
videos
All
Report Center
Industry Updates
In the Spotlight
Blog
reports
CIR Gives Bluebird Bio Something to Sing About: $9.3M
October 30, 2012
Share:
Gene therapy company
bluebird bio
has been awarded $9.3 million to continue its Phase ½ trial of a stem cell transplant therapy that could aid in the treatment of beta-thalassemia and sickle cell disease. The award came from the
California Institute for Regenerative Medicine
’s Strategic Partnership. Back in July, bluebird secured a hefty $60 million of Series D funding from
Deerfield Partners
,
RA Capital
,
Ramius Capital Group
,
ARCH Venture Partners
,
Third Rock Ventures
,
TVM Capital
and
Forbion Capital Partners
.
bluebird bio
Pharmaceuticals
Oncology
Cambridge, MA
$9.3 million
Grant
VIEW DETAILS
Share:
Tags
Private Equity
Venture Capital
related
Here are the PE & VC firms most affected by the solar eclipse
Swinging for the fences: Sports media startup takes on industry rife with layoffs
PE doubles down on VC-backed startups
Vision Fund 101: Inside SoftBank's $93B vehicle
MOST READ ARTICLES
The sky's the limit: 3 VC-backed companies making flying cars
Can VCs keep pace with the ICO market?
Investor Spotlight: The rapid rise of Thoma Bravo
VC investment in US agtech keeps growing [datagraphic]
Timeline: In seven years, WeWork built a $21B co-working empire
trending reports
3Q 2017
PitchBook Artificial Intelligence & Machine Learning Market Map
August 10, 2017
1H 2017
VC Valuations Report
August 09, 2017
A better way to do
VC, PE and M&A
The PitchBook Platform
